Roffman Miller Associates Inc. PA decreased its position in Pfizer, Inc. (NYSE:PFE) by 5.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,560 shares of the biopharmaceutical company’s stock after selling 883 shares during the period. Roffman Miller Associates Inc. PA’s holdings in Pfizer were worth $489,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. Davy Asset Management Ltd increased its stake in Pfizer by 0.5% in the fourth quarter. Davy Asset Management Ltd now owns 429,635 shares of the biopharmaceutical company’s stock worth $16,017,000 after buying an additional 2,124 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in Pfizer by 12.2% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,031,498 shares of the biopharmaceutical company’s stock worth $33,500,000 after buying an additional 112,465 shares in the last quarter. Tyers Asset Management LLC purchased a new stake in Pfizer during the fourth quarter worth approximately $4,228,000. Menta Capital LLC increased its stake in Pfizer by 16.3% in the fourth quarter. Menta Capital LLC now owns 151,316 shares of the biopharmaceutical company’s stock worth $4,915,000 after buying an additional 21,200 shares in the last quarter. Finally, Parallel Advisors LLC purchased a new stake in Pfizer during the fourth quarter worth approximately $1,351,000. Institutional investors own 69.94% of the company’s stock.
Shares of Pfizer, Inc. (NYSE:PFE) traded down 0.85% on Friday, reaching $32.67. The company’s stock had a trading volume of 15,490,145 shares. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $35.38. The company has a 50 day moving average price of $33.30 and a 200 day moving average price of $33.38. The company has a market cap of $194.30 billion, a P/E ratio of 23.90 and a beta of 1.00.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.92%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s dividend payout ratio is 94.12%.
TRADEMARK VIOLATION WARNING: This report was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.com-unik.info/2017/08/19/roffman-miller-associates-inc-pa-has-489000-stake-in-pfizer-inc-nysepfe-updated-updated.html.
A number of analysts have recently commented on the company. Jefferies Group LLC set a $35.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. Morgan Stanley reissued a “neutral” rating and issued a $35.00 price objective (down previously from $38.00) on shares of Pfizer in a research note on Monday, June 12th. Berenberg Bank set a $39.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, August 1st. Citigroup Inc. lowered Pfizer from a “neutral” rating to a “sell” rating and cut their target price for the stock from $38.00 to $31.00 in a research report on Tuesday, May 16th. Finally, BMO Capital Markets reaffirmed a “hold” rating and set a $33.00 target price on shares of Pfizer in a research report on Thursday, April 27th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $37.61.
In other news, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the transaction, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.